Cytotoxicity and antiviral activity evaluation of Cymbopogon spp hydroethanolic extracts
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Pharmaceutical Sciences |
Texto Completo: | https://www.revistas.usp.br/bjps/article/view/164769 |
Resumo: | Cymbopogon citratus and C. nardus are noteworthy among the several existing plant species displaying medicinal properties, due to the potential pharmacological activity of these species, including antiviral, antibacterial, antifungal and anti-trypanosomal activities. The objective of this study was to carry out in vitro toxicity tests of plant extracts from both species and analyze potential antiviral activity against Human mastadenovirus serotype 5 (HAdV-5). Two cell lines (A549 and VERO) were used and mitochondrial and lysosomal viability were determined by the MTT and neutral red assay, respectively, after two exposure times (24 hours and six days). The aim of these assays was to counteract the behavior of the extracts against the different cell lines and determine their non-toxic concentration range, in order to evaluate possible antiviral activity against HAdV-5. Plaque reduction and inhibition index of viral titer assays were performed using the maximum non-cytotoxic concentrations (MNCC) of each extract. The results indicate MNCC at 625 μg/mL for all extracts, except for Cymbopogon nardus obtained with 80% ethanol (CN80), which showed toxicity at concentrations higher than 312.5 μg/mL. CN80 was the only extract that displayed potential activity against HAdV-5, at a concentration of 75 μg/mL, becoming a candidate for extract fraction purification and/or the isolation of substances related to the observed antiviral activity. |
id |
USP-31_7d9b75f276d903bf61b0aacff47bf08e |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/164769 |
network_acronym_str |
USP-31 |
network_name_str |
Brazilian Journal of Pharmaceutical Sciences |
repository_id_str |
|
spelling |
Cytotoxicity and antiviral activity evaluation of Cymbopogon spp hydroethanolic extractsCymbopogon citratus/toxicityCymbopogon nardus/toxicityCellular viabilityHuman mastadenovirusPlants/extractsCymbopogon citratus and C. nardus are noteworthy among the several existing plant species displaying medicinal properties, due to the potential pharmacological activity of these species, including antiviral, antibacterial, antifungal and anti-trypanosomal activities. The objective of this study was to carry out in vitro toxicity tests of plant extracts from both species and analyze potential antiviral activity against Human mastadenovirus serotype 5 (HAdV-5). Two cell lines (A549 and VERO) were used and mitochondrial and lysosomal viability were determined by the MTT and neutral red assay, respectively, after two exposure times (24 hours and six days). The aim of these assays was to counteract the behavior of the extracts against the different cell lines and determine their non-toxic concentration range, in order to evaluate possible antiviral activity against HAdV-5. Plaque reduction and inhibition index of viral titer assays were performed using the maximum non-cytotoxic concentrations (MNCC) of each extract. The results indicate MNCC at 625 μg/mL for all extracts, except for Cymbopogon nardus obtained with 80% ethanol (CN80), which showed toxicity at concentrations higher than 312.5 μg/mL. CN80 was the only extract that displayed potential activity against HAdV-5, at a concentration of 75 μg/mL, becoming a candidate for extract fraction purification and/or the isolation of substances related to the observed antiviral activity.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2019-12-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/16476910.1590/s2175-97902019000118063Brazilian Journal of Pharmaceutical Sciences; Vol. 55 (2019); e18063Brazilian Journal of Pharmaceutical Sciences; v. 55 (2019); e18063Brazilian Journal of Pharmaceutical Sciences; Vol. 55 (2019); e180632175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/164769/157954Copyright (c) 2019 Brazilian Journal of Pharmaceutical Scienceshttp://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessChiamenti, LisandraSilva, Francini Pereira daSchallemberger, KarolineDemoliner, MerianeRigotto, CarolineFleck, Juliane Deise2019-12-04T12:54:08Zoai:revistas.usp.br:article/164769Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2019-12-04T12:54:08Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Cytotoxicity and antiviral activity evaluation of Cymbopogon spp hydroethanolic extracts |
title |
Cytotoxicity and antiviral activity evaluation of Cymbopogon spp hydroethanolic extracts |
spellingShingle |
Cytotoxicity and antiviral activity evaluation of Cymbopogon spp hydroethanolic extracts Chiamenti, Lisandra Cymbopogon citratus/toxicity Cymbopogon nardus/toxicity Cellular viability Human mastadenovirus Plants/extracts |
title_short |
Cytotoxicity and antiviral activity evaluation of Cymbopogon spp hydroethanolic extracts |
title_full |
Cytotoxicity and antiviral activity evaluation of Cymbopogon spp hydroethanolic extracts |
title_fullStr |
Cytotoxicity and antiviral activity evaluation of Cymbopogon spp hydroethanolic extracts |
title_full_unstemmed |
Cytotoxicity and antiviral activity evaluation of Cymbopogon spp hydroethanolic extracts |
title_sort |
Cytotoxicity and antiviral activity evaluation of Cymbopogon spp hydroethanolic extracts |
author |
Chiamenti, Lisandra |
author_facet |
Chiamenti, Lisandra Silva, Francini Pereira da Schallemberger, Karoline Demoliner, Meriane Rigotto, Caroline Fleck, Juliane Deise |
author_role |
author |
author2 |
Silva, Francini Pereira da Schallemberger, Karoline Demoliner, Meriane Rigotto, Caroline Fleck, Juliane Deise |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Chiamenti, Lisandra Silva, Francini Pereira da Schallemberger, Karoline Demoliner, Meriane Rigotto, Caroline Fleck, Juliane Deise |
dc.subject.por.fl_str_mv |
Cymbopogon citratus/toxicity Cymbopogon nardus/toxicity Cellular viability Human mastadenovirus Plants/extracts |
topic |
Cymbopogon citratus/toxicity Cymbopogon nardus/toxicity Cellular viability Human mastadenovirus Plants/extracts |
description |
Cymbopogon citratus and C. nardus are noteworthy among the several existing plant species displaying medicinal properties, due to the potential pharmacological activity of these species, including antiviral, antibacterial, antifungal and anti-trypanosomal activities. The objective of this study was to carry out in vitro toxicity tests of plant extracts from both species and analyze potential antiviral activity against Human mastadenovirus serotype 5 (HAdV-5). Two cell lines (A549 and VERO) were used and mitochondrial and lysosomal viability were determined by the MTT and neutral red assay, respectively, after two exposure times (24 hours and six days). The aim of these assays was to counteract the behavior of the extracts against the different cell lines and determine their non-toxic concentration range, in order to evaluate possible antiviral activity against HAdV-5. Plaque reduction and inhibition index of viral titer assays were performed using the maximum non-cytotoxic concentrations (MNCC) of each extract. The results indicate MNCC at 625 μg/mL for all extracts, except for Cymbopogon nardus obtained with 80% ethanol (CN80), which showed toxicity at concentrations higher than 312.5 μg/mL. CN80 was the only extract that displayed potential activity against HAdV-5, at a concentration of 75 μg/mL, becoming a candidate for extract fraction purification and/or the isolation of substances related to the observed antiviral activity. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-12-04 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/164769 10.1590/s2175-97902019000118063 |
url |
https://www.revistas.usp.br/bjps/article/view/164769 |
identifier_str_mv |
10.1590/s2175-97902019000118063 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/164769/157954 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2019 Brazilian Journal of Pharmaceutical Sciences http://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2019 Brazilian Journal of Pharmaceutical Sciences http://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
dc.source.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences; Vol. 55 (2019); e18063 Brazilian Journal of Pharmaceutical Sciences; v. 55 (2019); e18063 Brazilian Journal of Pharmaceutical Sciences; Vol. 55 (2019); e18063 2175-9790 1984-8250 reponame:Brazilian Journal of Pharmaceutical Sciences instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Brazilian Journal of Pharmaceutical Sciences |
collection |
Brazilian Journal of Pharmaceutical Sciences |
repository.name.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
bjps@usp.br||elizabeth.igne@gmail.com |
_version_ |
1787713371851718656 |